First-line panitumumab combined with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): data from a phase II, single-arm, multicentre study (20060314)

被引：0
|
作者：
Karthaus, M. [1 ]
Greil, R. [2 ]
Mineur, L. [3 ]
Letocha, H. [4 ]
Thaler, J. [6 ]
Hofheinz, R. [5 ]
Fernebro, E. [7 ]
Gamelin, E. [8 ]
DeCosta, L. [9 ]
Koehne, C.-H. [10 ]
机构：
[1] Klin Hamatol & Onkol, Klinikum Neuperlach, Munich, Germany
[2] Innere Med Klin 3, Salzburg, Austria
[3] Int Sainte Catherine, Avignon, France
[4] Onkol Kliniken, Vasteras, Sweden
[5] Klinikum Mannheim, Mannheim, Germany
[6] Klinikum Wels Grieskirchen, Wels, Austria
[7] Onkol Kliniken, Helsingborg, Sweden
[8] Ctr Paul Papin, Angers, France
[9] Amgen Ltd, Uxbridge, Middx, England
[10] Onkol Klinikum Oldenburg, Oldenburg, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [31] First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study
    Tsuji, Yasushi
    Satoh, Taroh
    Tsuji, Akihito
    Muro, Kei
    Yoshida, Motoki
    Nishina, Tomohiro
    Nagase, Michitaka
    Komatsu, Yoshito
    Kato, Takeshi
    Miyata, Yoshinori
    Mizutani, Naoko
    Hashigaki, Satoshi
    Lechuga, Maria Jose
    Denda, Tadamichi
    CANCER SCIENCE, 2012, 103 (08) : 1502 - 1507
  • [32] FINAL RESULTS OF A MULTICENTRE PHASE II TRIAL EVALUATING CETUXIMAB IN COMBINATION WITH FOLFIRINOX AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Samalin, E.
    Desseigne, F.
    Thezenas, S.
    Bibeau, F.
    Viret, F.
    Mineur, L.
    Assenat, E.
    Bleuse, J.
    Portales, F.
    Crapez, E.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2009, 20 : 20 - 20
  • [33] First line therapy of Panitumumab, a fully human antibody, in combination with FOLFIRI for the treatment (txt) of metastatic colorectal cancer (mCRC)
    Berlin, J.
    Posey, J.
    Tchekmedyian, S.
    Hu, E.
    Chan, D.
    Malik, I.
    Yang, L.
    MacDonald, M.
    Jerian, S.
    Hecht, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 185 - 185
  • [34] Impact of primary tumour location (PTL) on outcomes in patients (pts) with metastatic colorectal cancer (mCRC) undergoing first-line panitumumab (Pmab) plus FOLFIRI treatment
    Karthaus, Meinolf
    Van Den Eynde, Marc
    Mineur, Laurent
    Thaler, Josef
    Koukakis, Reija
    Berkhout, Marloes
    Gallego, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [35] A single-arm, multicenter, phase II study of panitumumab in combination with capecitabine/oxaliplatin in first line, wild-type KRAS metastatic colorectal cancer patients.
    Pectasides, Dimitrios G.
    Karavasilis, Vasilios
    Kotoula, Vassiliki
    Samantas, Epaminontas
    Alexopoulou, Zoi
    Zagouri, Flora
    Syrigos, Konstantinos N.
    Koureas, Andreas
    Dionysopoulos, Dimitrios
    Lazaridis, Georgios
    Efstratiou, Ioannis
    Apessou, Dimitra
    Pentheroudakis, George E.
    Papaxoinis, George
    Fountzilas, George
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] A phase I study of sorafenib with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): Safety and efficacy results
    Maroun, Jean Alfred
    Jonker, Derek J.
    Cripps, M. Christine
    Asmis, Timothy R.
    Goel, Rakesh
    Goodwin, Rachel Anne
    Marginean, Horia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [38] Impact of tumour RAS/BRAF status in a first-line study of panitumumab plus FOLFIRI in patients with metastatic colorectal cancer
    Karthaus, Meinolf
    Hofheinz, Ralf-Dieter
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Fernebro, Eva
    Oliner, Kelly S.
    Boedigheimer, Michael
    Twomey, Brian
    Zhang, Ying
    Demonty, Gaston
    Koehne, Claus-Henning
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1215 - 1222
  • [39] First-line treatment for metastatic colorectal cancer (MCRC) patients (pts). Results of a randomized phase IIITMO study
    Bajetta, E.
    Di Bartolomeo, M.
    Ferrario, E.
    Beretta, E.
    Rabbi, C.
    Isa, L.
    Barone, C.
    Lo, S.
    Zilembo, Vullo N.
    ANNALS OF ONCOLOGY, 2005, 16 : 48 - 48
  • [40] Efficacy and safety of camrelizumab combined with chemotherapy in the first-line treatment of advanced gastric cancer: a single-arm, phase II study
    Liu, Wenlou
    Wang, Hongmei
    Zhao, Yang
    Ge, Yan
    Tang, Juangjuang
    Cao, Menghan
    Matsas, Silvio
    Breadner, Daniel Adam
    Qin, Xiaobing
    Han, Zhengxiang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04)
12345